Dashboard › CL1: Health › Key Facts
HORIZON-HLTH-2026-01-TOOL-07

Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

CSA Cluster 1 €3,900,000 16 Apr 2026
Topic Code HORIZON-HLTH-2026-01-TOOL-07 F&T Portal
Call Identifier HORIZON-HLTH-2026-01 Call 01 — single stage (2026)
Instrument HORIZON-CSA Coordination and Support Action
Budget Model Lump Sum HORIZON-AG-LS
Funding Rate 100% Annex G — CSA = 100%
Page Limit (Part B) 28 pages CSA + lump sum (Annex A)
Evaluation Thresholds 4 / 4 / 4 · cum. 12 Non-standard — topic override
Expected Projects 1 ~€3.9M per project (WP stated)
Destination Developing and using new tools, technologies and digital solutions for a healthy society WP Part 4
Cluster / Pillar Cluster 1 / Pillar II Health
China Eligibility Eligible ✓ CSA not restricted (RIA/IA only)
Special Conditions Max 10 CoEs network Network limited to 10 centres
Verify: Open this topic on the F&T Portal →  ·  Sources: General Annexes 2026-2027, WP Part 4
See what a full Decision Brief looks like →
Compliance traps · Scoring playbook · Consortium blueprint · 2 free examples available
China is eligible for this topic. The destination’s China restriction applies to RIA and IA only — CSA is not restricted.
This topic uses non-standard evaluation thresholds: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.

Expected Outcomes

  1. In line with the objectives of the “Strategy for European Life Sciences”, the EU successfully translates a strategic priority into an implementable action plan for building technological and innovation leadership on a global stage.
  2. Europe, including regions, profits from an increased capacity, accessibility, coordination of its Advanced Therapies Medicinal Products (ATMP) infrastructures.
  3. The European economy benefits from more ATMP innovations being developed and commercialised in the EU.
  4. Patients across the EU gain faster access to innovative ATMPs thanks to increased and focused public Research and Development (R&D) investment, harmonised policies and strategies for ATMP development and uptake in healthcare systems.

Want the full analysis?

The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.

Compliance traps Scoring playbook Consortium blueprint Positioning guide Red flags Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day
Disclaimer: This page is produced using advanced AI analysis and reviewed by an experienced EU grant engineer. While we take care to ensure accuracy, the information may contain errors or become outdated. It is the applicant’s sole responsibility to verify all facts against the official EU Funding & Tenders Portal before making any decisions. Global Disruption accepts no liability for errors, omissions, or decisions made based on this content. No refunds are offered for Key Facts pages or Decision Briefs.